Eli Lilly and Co. and its partner cannot stop competitors from selling generic versions of testosterone treatment Axiron, a federal judge in Indianapolis has ruled. U.S. Judge Sarah Evans Barker on Monday concluded that a formulation patent originally granted for the drug was invalidated and therefore would not be infringed by the commercialization of generic versions. The court also ruled the applicator patent is valid but was not infringed.
http://www.ibj.com/articles/60073-lilly-partner-lose-court-fight-over-testosterone-treatment
http://www.ibj.com/articles/60073-lilly-partner-lose-court-fight-over-testosterone-treatment
